The PIONEER study revealed that 46.3% (671/1450) of Asian patients and 46.7% (346/741) of mainland Chinese patients with advanced lung adenocarcinoma were EGFR-sensitizing mutation positive and suitable for receiving EGFR-TKI therapy.4,5. The gene discussed is EGFR; the disease is lung adenocarcinoma.